Propanc Biopharma reports pilot study shows anti-tumor efficacy for PRP proenzyme formulation in pancreatic, ovarian cancer
Bitget2026/10/14 12:32- Propanc Biopharma reported results already presented in a newly published peer-reviewed pilot study in Scientific Reports on its PRP proenzyme therapy.
- Preclinical tests showed PRP slowed tumor growth and reduced spread-related behavior in pancreatic and ovarian cancer models, with tolerable safety.
- Separate UK Specials use in advanced cancers indicated longer-than-expected survival for a subset of patients, with no severe treatment-related events reported.
- The data support continued development of PRP as a long-term, non-cytotoxic approach aimed at reducing recurrence and metastasis in solid tumors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
